ArticleScientific reports2025
Population based analysis of twenty year incidence trends of pediatric Hodgkin lymphoma in the United States.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hodgkin lymphoma (HL) is the most diagnosed cancer among young adults between the ages of 15 to 19 years. This study aims to update the HL incidence trends by age, sex, and race/ethnicity among children and adolescents in the United States (US) from 2000 to 2020. Surveillance, Epidemiology, and End Results (SEER) 22 data were utilized to estimate counts, age-adjusted incidence rates, and trends. HL patients were identified using the International Classification of Diseases for Oncology version 3. The annual percent change (APC) and average APC (AAPC) were computed using joinpoint regression. Between 2000 and 2019, the US documented a cumulative total of 10,007 of pediatric HL spanning various age categories. Classical HL comprised the majority (92.98%) of cases, predominantly affecting non-Hispanic Whites (53.28%) and individuals aged 15-19 years (66.35%). Trends in AAPCs showed no notable alterations. However, both incident cases and rates demonstrated a consistent rise with increasing age. While no significant changes were observed in the overall incidence trend of pediatric HL from 2000 to 2019, discrepancies persist among the results of different studies. Additional research is warranted to explore potential underlying factors that may influence these observed trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.